ARTICLE
|
doi:10.20944/preprints202401.0265.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
Myeloproliferative neoplasms; JAK2-V617F mediated resistance; ruxolitinib; JAK2-STAT5 signaling; HSP90 inhibition
Online: 3 January 2024 (14:39:52 CET)